Guard Therapeutics International AB
Clinical-stage biotech developing therapies to prevent acute kidney injury.
GUARD | ST
Overview
Corporate Details
- ISIN(s):
- SE0021181559
- LEI:
- 549300DTX7T87FGYG180
- Country:
- Sweden
- Address:
- Box 5216, 102 45 Stockholm
- Website:
- https://guardtherapeutics.com/
Description
Guard Therapeutics International AB is a clinical-stage biotechnology company focused on developing novel therapies for diseases with significant unmet medical needs, particularly kidney diseases. The company's research is centered on the endogenous protein Alpha-1-Microglobulin (A1M), which possesses cell-protective and antioxidative properties. Its lead drug candidate, RMC-035, is a recombinant form of A1M being developed as an intravenous treatment to prevent acute kidney injury. The candidate has been evaluated in a Phase 2b clinical trial (POINTER) in patients undergoing open-heart surgery, a procedure associated with a high risk of kidney complications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Guard Therapeutics International AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Guard Therapeutics International AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Guard Therapeutics International AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
